Posts Tagged: "acute myeloid leukemia"

$1.5 billion Celator purchase buoys the financial future of Jazz Pharmaceuticals’ oncology division

Of particular interest in this deal is a drug in Celator’s pipeline is Vyxeos (cytarabine:daunorubicin), an injectable liposomal treatment for blood cancers, especially acute myeloid leukemia (AML). The treatment, which has received a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for fast-tracked approval, recently achieved positive results in a Phase 3 trial. Patients with high-risk, or secondary, AML who received Vyxeos injections saw a significant increase in overall survival rates, 41.5 percent for Vyxeos-treated patients versus 27.6 percent for other patients in a year’s time.

Bolder initiatives needed to take next steps in fight against cancer

February 4 is World Cancer Day… There has been steady progress made in the history of treating cancers of many types since the administration of former U.S President Richard Nixon, according to Dr. Boris Pasche, the Director of the Wake Forest Baptist Medical Center’s Comprehensive Cancer Center. “In my opinion, government should embark on bold new initiatives in cancer treatment,” Pasche said. He did note that, while what President Obama says as a statesman doesn’t change the humbling reality that many cancers have so far stumped medical scientists. Nevertheless, increased investments into cancer research have dramatically impacted survival rates. Over the past decade, most cancers show a better outcome than they did ten years ago. “Bolder initiatives with disruptive approaches to cancer are in order if we want to make leaps forward more quickly,” Pasche said.

Hybrigenics gets Orphan Drug designation for the treatment of Acute Myeloid Leukemia

Hybrigenics (ALHYG), a French bio-pharmaceutical company with a focus on research and development of new treatments against proliferative diseases, has announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to inecalcitol for the treatment of acute myeloid leukemia (AML) in the United States. In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation allows the company receiving the designation to leverage a wide range of financial and regulatory benefits, including government and institutional grants, and waiver of FDA user fees for the potential submission of a New Drug Application.